Enhanced Genomics and ALBORADA Drug Discovery Institute Accelerate Alzheimer’s Drug Discovery

A pioneering collaboration between biotech innovator Enhanced Genomics and The ALBORADA Drug Discovery Institute at the University of Cambridge has delivered a major breakthrough in Alzheimer’s research. The partnership, supported by Alzheimer’s Research UK, is already generating multiple novel drug targets that were previously undetectable using traditional genomic methods.

By harnessing Enhanced Genomics’ proprietary 3D multi-omics platform, scientists have been able to map complex gene-regulatory interactions at an unprecedented scale and resolution. This has revealed critical new insights into the underlying biology of Alzheimer’s disease and accelerated the discovery of high-confidence, genetically validated drug targets.

“This collaboration marks a turning point in how we discover drugs for complex diseases like Alzheimer’s,” said Dr. Dan Turner, Chief Scientific Officer at Enhanced Genomics. “Our platform doesn’t just look at the genome—it interprets how different regions of DNA interact in 3D space across specific human cell types. This gives us the power to uncover therapeutic targets hidden in the non-coding genome, something conventional tools simply can’t do.”

The ALBORADA Drug Discovery Institute, based at the University of Cambridge, has used these findings to open new research pathways into drug development. “The insights provided by Enhanced’s technology have already led us to previously unknown targets with real therapeutic potential,” said Dr. John Skidmore, CSO at The ALBORADA Drug Discovery Institute. “This could significantly advance our ability to develop effective treatments for Alzheimer’s disease.”

Alzheimer’s Research UK, the UK’s leading dementia research charity, sees this partnership as a model for future industry-academic collaborations. “This is the kind of ambitious, high-impact science we need to bring hope to the millions affected by dementia,” said Dr. Julia Dudley, Head of Strategic Programmes. “By combining cutting-edge technology with deep disease expertise, we’re accelerating progress toward the next generation of treatments.”

The collaboration not only delivers immediate value in Alzheimer’s research, but also underscores the wider potential of Enhanced’s 3D multi-omics platform. By defining causal biology from disease-associated genetic variants, the technology dramatically improves both the speed and likelihood of success in early drug discovery.

Looking ahead, Enhanced Genomics and The ALBORADA Drug Discovery Institute are exploring ways to expand their work into other neurodegenerative diseases. The company is also actively seeking new partnerships with pharmaceutical and biotech organizations interested in incorporating 3D multi-omics into their own drug discovery pipelines.

About Enhanced Genomics:

Enhanced Genomics is a biotechnology company revolutionizing drug discovery through its proprietary 3D multi-omics platform, capable of identifying high-confidence therapeutic targets from disease-associated variants across the entire genome. The platform enables faster, more efficient, and more successful drug development for common diseases with high unmet need.

About The ALBORADA Drug Discovery Institute:

Established by Alzheimer’s Research UK, The ALBORADA Drug Discovery Institute focuses on developing treatments that tackle the biological mechanisms driving neurodegenerative diseases, including Alzheimer’s.

About Alzheimer’s Research UK:

Alzheimer’s Research UK is the UK’s leading dementia research charity, dedicated to accelerating the discovery of new treatments and, ultimately, a cure for dementia.